Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

Inclusion Criteria: * Age 12 years and above. * Subject able and willing to self-administer tralokinumab with Device A. * Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD. * History of AD for ≥1 year. * A recent history (within 1 year before the screening visit) of inadequate response to treatment with topical medication or for whom topical treatments are otherwise medically inadvisable. * AD involvement of ≥10% body surface area at screening and baseline. * An EASI score of ≥12 at screening and ≥16 at baseline. * An IGA score of ≥3 at screening and at baseline. * Applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before baseline. Exclusion Criteria: * Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment. * Use of tanning beds or phototherapy within 4 weeks prior to baseline. * Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 4 weeks prior to baseline. * Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase 4 inhibitors, or topical Janus kinase inhibitors within 2 weeks prior to baseline. * Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents 3 to 6 months prior to baseline. * Active skin infections within 1 week prior to baseline. * Clinically significant infection within 4 weeks prior to baseline. * A helminth parasitic infection within 6 months prior to the date informed consent is obtained. * Tuberculosis requiring treatment within 12 months prior to screening. * Known primary immunodeficiency disorder.